TY - JOUR
T1 - Future Perspectives on the Automation and Biocompatibility of Molecularly Imprinted Polymers for Healthcare Applications
AU - Garg, Saweta
AU - Singla, Pankaj
AU - Kaur, Sarbjeet
AU - Canfarotta, Francesco
AU - Velliou, Eirini
AU - Dawson, James A.
AU - Kapur, Nikil
AU - Warren, Nicholas J.
AU - Amarnath, Shoba
AU - Peeters, Marloes
PY - 2025/2/11
Y1 - 2025/2/11
N2 - Molecular recognition is of crucial importance in several healthcare applications, such as sensing, drug delivery, and therapeutics. Molecularly imprinted polymers (MIPs) present an interesting alternative to biological receptors (e.g., antibodies, enzymes) for this purpose since synthetic receptors overcome the limited robustness, flexibility, high-cost, and potential for inhibition that comes with natural recognition elements. However, off the shelf MIP products remain limited, which is likely due to the lack of a scalable production approach that can manufacture these materials in high yields and narrow and defined size distributions to have full control over their properties. In this Perspective, we will confer how breakthroughs in the automation of MIP design, manufacturing, and evaluation of performance will accelerate the (commercial) implementation of MIPs in healthcare technology. In addition, we will discuss how prediction of the in vivo behavior of MIPs with animal-free technologies (e.g., 3D tissue models) will be critical to assess their clinical potential.
AB - Molecular recognition is of crucial importance in several healthcare applications, such as sensing, drug delivery, and therapeutics. Molecularly imprinted polymers (MIPs) present an interesting alternative to biological receptors (e.g., antibodies, enzymes) for this purpose since synthetic receptors overcome the limited robustness, flexibility, high-cost, and potential for inhibition that comes with natural recognition elements. However, off the shelf MIP products remain limited, which is likely due to the lack of a scalable production approach that can manufacture these materials in high yields and narrow and defined size distributions to have full control over their properties. In this Perspective, we will confer how breakthroughs in the automation of MIP design, manufacturing, and evaluation of performance will accelerate the (commercial) implementation of MIPs in healthcare technology. In addition, we will discuss how prediction of the in vivo behavior of MIPs with animal-free technologies (e.g., 3D tissue models) will be critical to assess their clinical potential.
U2 - 10.1021/acs.macromol.4c01621
DO - 10.1021/acs.macromol.4c01621
M3 - Article
SN - 0024-9297
VL - 58
SP - 1157
EP - 1168
JO - Macromolecules
JF - Macromolecules
IS - 3
ER -